RT Journal Article
SR Electronic
T1 The novel cardiokine GDF3 predicts adverse fibrotic remodeling post-myocardial infarction
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.31.21257816
DO 10.1101/2021.05.31.21257816
A1 Masurkar, Nihar
A1 Bouvet, Marion
A1 Logeart, Damien
A1 Claude, Olivier
A1 Roux, Maguelonne
A1 Delacroix, Clément
A1 Bergerot, Damien
A1 Mercadier, Jean-Jacques
A1 Sirol, Marc
A1 Gellen, Barnabas
A1 Livrozet, Marine
A1 Fayol, Antoine
A1 Robidel, Estelle
A1 Trégouët, David-Alexandre
A1 Marazzi, Giovanna
A1 Sassoon, David
A1 Valente, Mariana
A1 Hulot, Jean-Sébastien
YR 2021
UL http://medrxiv.org/content/early/2021/06/01/2021.05.31.21257816.abstract
AB Background Myocardial infarction (MI) induces a repair response that ultimately generates a stable fibrotic scar. Although the scar prevents cardiac rupture, an excessive profibrotic response impairs optimal recovery.Objective To explore the regulation of fibroblasts proliferation through a paracrine action of cardiac stromal cells post-MIMethods We carried out a bioinformatic secretome analysis of cardiac stromal PW1+ cells isolated from normal and post-MI mouse hearts to identify novel secreted proteins. Functional assays were used to screen secreted proteins that promote fibroblast proliferation. The expressions of secreted proteins candidates were subsequently analyzed in mouse and human hearts and plasmas. The relation between levels of circulating protein candidates and adverse post-MI cardiac remodeling was examined in a cohort of 80 patients with a first ST-elevation MI and serial cardiac magnetic resonance imaging (MRI) evaluations.Results Cardiac stromal PW1+ cells undergo a change in paracrine behavior post-MI and secrete factors that promote fibroblast proliferation. Among these factors, growth differentiation factor 3 (GDF3), a member of the transforming growth factor-β family, was markedly upregulated in the ischemic hearts and induced fibroblast proliferation at high level. In humans, GDF3 was detected in the plasma at day 4 post-MI and GDF3 circulating levels were significantly associated with an increased risk of adverse remodeling 6-month post-MI (adjusted Odds Ratio (OR) = 1.76 [1.03 - 3.00], p = 0.037).Conclusions Our findings define a mechanism for the pro-fibrotic action of cardiac stromal cells through secreted cardiokines, such as GDF3, a candidate marker of adverse fibrotic remodeling following MI.Competing Interest StatementJSH reports research grants from Bioserenity, Sanofi, Servier and Novo Nordisk; speaker, advisory board or consultancy fees from Amgen, Astra Zeneca, Bayer, Bioserenity, Bristol-Myers Squibb, Novartis, Novo-Nordisk, all unrelated to the present work. Other authors declare no competing financial interests.Clinical TrialNCT01113268Funding StatementThis work was supported by a grant from the Fondation Leducq (13CVD01), Federation Francaise de Cardiologie, Era-CVD (ANR-16-ECVD-0011-03), ANR PACIFIC (ANR-18-CE14-0032-02), ANR REVIVE (Laboratoire d Excellence, ANR-10-LABX-73) and GENMED Laboratory of Excellence on Medical Genomics (ANR-10-LABX-0013).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Animal studies :CEEA34 and French ministry of research, N2019050221153452 Human studies : Sponsor: Assistance Publique Hopitaux de Paris, Ethics committee : CPP Ile de France I authorization 2010-fev.-12233All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yeson requestCELA1chymotrypsin-like elastase family member 1FACSfluorescence-activated cell sortingFDGfluorescent substrate 5-dodecanoylaminofluorescein di-β-D-galactopyranosideGDF3growth differentiation factor-3LADleft anterior descending coronary artery LADLVEDVileft ventricular end-diastolic volume indexed for body surface areaLVEFleft ventricular ejection fractionNDPnorrin cystine knot growth factorMEFsmouse embryonic fibroblastsMIMyocardial InfarctionMRIMagnetic resonance imagingPROK2prokineticin 2STEMIST-elevation myocardial infarctionTGF-βtransforming growth factor-beta